Research and Development

The Union Cabinet on Wednesday approved the National Quantum Mission (NQM) with a total outlay of Rs 6,003.65 crore for the period 2023-24 to 2030-31 to scale up research and development and create an innovative ecosystem in quantum…

<!-- Name:DistributionId Value:8744909 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value: -->…

Opinions expressed by Entrepreneur contributors are their own. It's not hard to imagine this scenario: An entrepreneur experiences a problem and decides to build a solution to solve it. It works well, they love the solution…

MIAMI, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc.(OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery technologies for the next generation of…

MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health…

Suzuki, which already builds combustion engine cars in India, will start producing EVs at its factory in 2025 Suzuki, which already builds combustion engine cars in India, will start producing EVs at its factory in 2025 Suzuki Motor Corp.…

GAITHERSBURG, Md., June 24, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 (Anthrax…

Saskatoon, Canada, June 21, 2022 (GLOBE NEWSWIRE) -- The Global Institute for Food Security (GIFS) at the University of Saskatchewan is pleased to announce the successful hiring of its first Chief Scientific Officer, Nancy Tout (PhD).…

IT company Pure Storage has opened its new Research and Development(R&D) Center in Bangalore. The new center, as per the company, is a key component of Pure Storage’s global innovation engine and a commitment to the government’s ‘Make…

GAITHERSBURG, Md., March 11, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and…